ST-JUDE MEDICAL VALVE PROSTHESIS - AN ANALYSIS OF LONG-TERM OUTCOME AND PROGNOSTIC FACTORS

Citation
Lf. Debetaz et al., ST-JUDE MEDICAL VALVE PROSTHESIS - AN ANALYSIS OF LONG-TERM OUTCOME AND PROGNOSTIC FACTORS, Journal of thoracic and cardiovascular surgery, 113(1), 1997, pp. 134-148
Citations number
30
Categorie Soggetti
Cardiac & Cardiovascular System",Surgery
ISSN journal
00225223
Volume
113
Issue
1
Year of publication
1997
Pages
134 - 148
Database
ISI
SICI code
0022-5223(1997)113:1<134:SMVP-A>2.0.ZU;2-#
Abstract
Between 1979 and 1984, 321 patients received 354 St. Jude Medical pros theses (193 aortic, 94 mitral, 1 tricuspid, and 32 multiple valve repl acements). Follow-up was 96% complete (2967 patient-years; mean 9.5 ye ars per patient). Actuarial event-free rates at 10 years and linearize d rates (in parentheses) of late complications were as follows: emboli sm, 85.0% +/- 2.3% (2.3% per patient-year); anticoagulant-related hemo rrhage, 74.8% +/- 2.7% (3.3% per patient-year); cerebrovascular accide nt, 81.8% +/- 2.5% (2.6% per patient-year); prosthesis thrombosis, 98. 5% +/- 0.7% (0.1% per patient-year); endocarditis, 97.2% +/- 1.1% (0.4 % per patient-year); prosthesis dysfunction, 97.1% +/- 1.0% (0.4% per patient-year); hemolytic anemia, 98.5% +/- 0.7% (0.1% per patient-year ); reoperation, 97.4% +/- 1.0% (0.4% per patient-year); overall mortal ity, 63.3% +/- 2.7% (4.2% per patient-year); and valve-related death ( including sudden death), 84.7% +/- 2.2% (1.4% per patient-year). Indep endent preoperative risk factors were as follows: (1) for embolism, ca rdiac failure as indication for operation and history of prior systemi c embolism; (2) for cerebrovascular accidents, the same two factors an d age; (3) for endocarditis, diabetes, chronic alcoholism, and aortic valve replacement; (4) for overall mortality, age, ejection fraction ( or cardiac index or cardiothoracic index), chronic alcoholism, and his tory of systemic embolism; and (5) for valve-related death, chronic al coholism, degenerative cause of valve disease, and prosthetic diameter 23 mm or smaller. Ninety percent of survivors were in New York Heart Association functional class I or II at the end of follow-up. In concl usion, this study confirms the excellent durability of the St. Jude Me dical valve and the remarkable functional benefit for the majority of the patients. However, prosthesis-related complications are still comm on, particularly for small-diameter prostheses. Outcome is strongly re lated to the patient's preoperative cardiac condition and to the adequ acy of anticoagulation control.